In four cases of therapeutic abortion by laparotomy, tracer amounts of oestrone-6,7-3H and 17\g=b\-oestradiol-16-14C were injected into the umbilical vein 20 minutes prior to the interruption of gestation, and the radioactive material recovered from the placenta and various foetal tissues was analysed. 
More than 92 per cent of the radioactive material recovered from the foetus, but less than 15 per cent of that present in the placenta, was in a conjugated form. Among the foetal tissues studied, the highest percentage of unconjugated (free) radioactive material (25 per cent) occurred in the adrenals.
Determination of the isotopic ratios revealed that complete interconversion of injected material was approached only by the oestrone and 17\ g=b\ \ x =r eq-\ oestradiol isolated from the conjugated fraction of the liver. Approximately 10 per cent of the radioactive material recovered from the foetal liver and smaller amounts of that found in the placenta and residual foetal tissues were isolated and identified as oestriol. The isotopic ratio of oestriol isolated from different sources approached very closely that of conjugated oestrone and 17\g=b\-oestradiol in the foetal liver, but was distinctly different from the isotopic ratio of free and conjugated oestrone and 17\g=b\-oestradiol in all other tissues.
At least 9 additional metabolites were detected in the conjugated fraction of the foetal liver. One of them was identified as 15\g=a\-hydroxy-17\g=b\\x=req-\ oestradiol, another one as 16-(or possibly 17-) epioestriol, and two were ring D ketolic oestrogens, most probably 16\g=a\-hydroxyoestrone and 16-oxo-17/?-oestradiol. The isotopie ratios of all identified compounds were similar to those of oestrone and 17/S-oestradiol isolated from the same fraction.
It is concluded that in the foeto-placental unit at midpregnancy, the liver is the main site of oestrone and 17/S-oestradiol metabolism and that this metabolism takes place predominantly in a conjugated form, most prob¬ ably in form of 3-sulphates.
Accumulating evidence indicates that oestrone (OEj) and 17/S-oestradiol (OE2) are extensively metabolised in the human foeto-placental unit (for a review: Diczfalusy 1964) . Thus it was shown that OEj and OE» are rapidly sulphury 1-ated by foetal tissues and that the oestrogen sulphates thus formed are hydro¬ lysed by the placenta (Haynes el al. 1964) . It (Engel et al. 1962 ). Furthermore, OE3 was isolated from the conjugated fraction of liver tissue following perfusion of previable foetuses with oestrone sulphate (Emerman et al. 1964) . Moreover, when déhydroépiandrostérone or its sulphate was in¬ jected into a uterine artery, OE3 was detected in the placenta and a 16a-hydroxyoestrone-like compound in the foetus (Boité et al. 1964 b) . These results suggested that in midpregnancy 16-hydroxylation of oestrogens takes place in the foetal-but not in the placental compartment.
On the other hand, when OE2 was perfused through previable foetuses or was injected into the intact foeto-placental unit, the evidence for OE3 for¬ mation was inconclusive (Haynes et al. 1964) .
In (1963 b) with slight modifications: the compounds were dissolved in 0.5 ml of 50 %> (v/v) ethanol rather than in propylene glycol, and the products of conception were removed 20 minutes after injection. At the end of the experiment, the cord was still pulsating, indicating that the foeto-placental circulation was maintained during the experiment.
Material and Methods
Abbreviations and trivial names Steroids2)-. DHA is dehydroe/jiandrosterone (3/?-hydroxy-androst-5-en-17-one), DHAS: dehydroe/uandrosterone sulphate, OE¡: oestrone») (3-hydroxy-oestra-l,3,5(10)-trien-17-one), OE^SS: oestrone 3-sulphate, 2MOE1: 2-methoxyoestroneb)(2,3-dihydroxyoestra-l,3,5(10)-trien-17-one, 2-methyl ether), 3MOE{: oestrone 3-methyl ethera), 3MOE]Th: the thiosemicarbazone of oestrone 3-methyl ether, 6oxoOEl: 6-oxooestroneb) (3-hydroxy-oestra-l,3,5(10)-triene-6,17-dione), ß ^: 6a-hydroxyoestroneb) (3,6a-dihydroxy-oestra-l,3,5(10)-trien-17-one), ^: 15a-hydroxyoestroneh) (3,15a-dihydroxy-oestra-l,3,5(10)-trien-17-one), 16aHOOE1: 16a-hydroxyoestroneb) (3,16a-dihydroxy-oestra-l,3,5(10)-trien-17-one), 16ß : 16/?-hydroxyoestronel>) (3,16/î-dihydroxy-oestra-l,3,5(10)-trien-17-one), OE2: 17/?-oestradiola) (oestra-l,3,5(10)-triene-3,17/?-diol), 2MOE2: 2-methoxy-17/?-oestradioll>) (oestra-l,3,5(10)-triene-2,3,17/?-triol-2-methyl ether), 3MOE2: 17/?-oestradiol 3-methyl ethera), 3MOE2Ac: the 17-acetate of 17/?-oestradiol 3-methyl ether, 6aHOOE2: 6a-hydroxy-17/?-oestradiolb) (oestral,3,5(10)-triene-3,6a,17/?-triol), 15oxoOE2: lS-oxo-U/î-oestradiol (3,17,5-dihydroxyoestra-l,3,5(10)-trien-15-one), 15aHOOE2: 15a-hydroxy-17/?-oestradiolc)0 (oestral,3,5(10)-triene-3,15a,17/?-triol), 16oxoOE2: 16-oxo-17/í-oestradiol¡0 (3,17/î-dihydroxyoestra-l,3,5(10)-trien-16-one), 16oxol7aOE.y. 16-oxo-17a-oestradiol (3,17a-dihydroxyoestra-l,3,5(10)-trien-16-one), OE3: oestriola) (oestra-l,3,5(10)-triene-3,16a,17/?-triol), OE3-3S: oestriol 3-sulphate, 16epiOEs: 16-e//ioestriolb)(oestra-l,3,5(10)-triene-3,16/?,17/3-triol), 17epiOEs-. 17-e/n'oestriol (oestra-l,3,5(10)-triene-3,16«,17a-triol), 16,17epiOE3: 16,17-e/noestriold) (oestra-l,3,5(10)-triene-3,16p\17a-triol), 3MOE3: oestriol 3-methyl ether»), 2HOOEs: 2-hydroxyoestrior=) (oestra-l,3,5(10)-triene-2,3,16a,17/î-tetrol), 6 3: öf-hydroxyoestriolb) (oestra-l,3,5(10)-triene-3,6f,l6a,17/?-tetrol), 6oxoOE3: 6-oxo-oestriol (3,16a,17/?-trihydroxy-oestra-l,3,5(10)-trien-6-one), 2MOE3: 2-methoxyoestriol 3, 3, 16a, 17pMetrol, Collection of material for analysis.
Upon completion of the experiment, the foetus and placenta were removed, the membranes and cord separated, and the foetal adrenals, liver and lungs dissected out and extracted separately. The residual foetal tissues (designated as »residual foetus«) were extracted together.
Twenty-four hour urine specimens were collected for 4 days.
Extraction procedure and separation of ether-soluble (free) from water-soluble (con¬ jugated) radioactive material was carried out as described by Mikhail et al. (1963 b The data of 
